	US 12,467,098 B2
	Methylated markers for colorectal cancer
Susanne Pedersen, North Ryde (AU); Lawrence LaPointe, Edison, NJ (US); Rohan Baker, North Ryde (AU); Amber C. Donahue, Rancho Santa Margarita, CA (US); Yen-lin Peng, Mission Viejo, CA (US); and Frederic Waldman, San Juan Capistrano, CA (US)
Assigned to Quest Diagnostics Investments LLC, Secaucus, NJ (US); and Clinical Genomics PTY Ltd, North Ryde (AU)
Filed by Quest Diagnostics Investments LLC, Secaucus, NJ (US); and Clinical Genomics PTY Ltd, North Ryde (AU)
Filed on Oct. 31, 2022, as Appl. No. 17/977,723.
Application 17/977,723 is a division of application No. 15/315,874, granted, now 11,486,007, previously published as PCT/US2015/033968, filed on Jun. 3, 2015.
Claims priority of provisional application 62/007,687, filed on Jun. 4, 2014.
Prior Publication US 2023/0212685 A1, Jul. 6, 2023
Int. Cl. C12Q 1/68 (2018.01); C12P 19/34 (2006.01); C12Q 1/6886 (2018.01)

CPC C12Q 1/6886 (2013.01) [C12Q 2600/118 (2013.01); C12Q 2600/154 (2013.01); C12Q 2600/158 (2013.01)]

11 Claims

1. A kit for multiplexed colorectal neoplasm screening, comprising:

(i) a set of oligonucleotide primers suitable for carrying out a multiplex amplification reaction comprising a primer pair specific for a Septin 9 gene, a primer pair specific for a Ikaros family zinc-finger 1 (IKZF1) gene, and a primer pair specific for a branched-chain aminotransferase 1 (BCAT1) gene, wherein the primer pair specific for the Septin 9 gene consists of SEQ ID NOs: 1 and 2; the primer pair specific for the IKZF1 gene consists of SEQ ID NOs: 4 and 5; and the primer pair specific for the BCAT1 gene consists of SEQ ID NOs: 7 and 8;

(ii) a set of fluorescently labelled oligonucleotide probes comprising a probe specific for the Septin 9 gene, a probe specific for the IKZF1 gene, and a probe specific for the BCAT1 gene; and

(iii) one or more reagents capable of converting unmethylated cytosine bases to uracil sulfonate.